Merck plans evaluation of spin-signal MR

Article

GE Healthcare’s gas-based MRI imaging strategy may find a home, if tests of the technology by Merck pan out. The pharmaceutical company plans to audition GE’s Spin Signal Technology (SST) utilizing hyperpolarized xenon 129 gas for use in assessing its experimental respiratory treatments.

GE Healthcare's gas-based MRI imaging strategy may find a home, if tests of the technology by Merck pan out. The pharmaceutical company plans to audition GE's Spin Signal Technology (SST) utilizing hyperpolarized xenon 129 gas for use in assessing its experimental respiratory treatments.

GE Healthcare has granted Merck access to the technology and its novel molecular imaging agent, which allows quantitative MR imaging of the lungs. Merck will assess whether SST is more sensitive than currently available tests used to gauge the function of diseased lungs.GE Healthcare has been looking for viable commercial applications for the technology since acquiring the rights following its merger with Amersham in 2004.

Newsletter

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Recent Videos
Diagnostic Imaging’s Weekly Scan: October 5 — October 11
Diagnostic Imaging’s Weekly Scan: September 28 — October 4
MRI Research Shows ‘Virtually Complete Abrogation’ of New Lesions with Switch to Ofatumumab for Multiple Sclerosis Patients
© 2025 MJH Life Sciences

All rights reserved.